临床医生可通过观察眼底视网膜血管及其分支对人体是否患有疾病进行早期诊断,但由于视网膜中的血管错综复杂,模型在分割时会出现对微细血管分割精确度不足的问题。为此,提出一种结合残差模块Res2-net以及高效通道注意力机制(efficient c...临床医生可通过观察眼底视网膜血管及其分支对人体是否患有疾病进行早期诊断,但由于视网膜中的血管错综复杂,模型在分割时会出现对微细血管分割精确度不足的问题。为此,提出一种结合残差模块Res2-net以及高效通道注意力机制(efficient channel attention,ECA)的D-Linknet模型。首先,利用Res2-net代替基础模型中的残差模块Res-net以提升每个网络层的感受野;其次,在Res2-net中添加一种结合压缩激励(squeeze and excitation,SE)和门通道(gated channel transformation,GCT)的注意力机制模块,改善处于复杂背景下的血管分割效果和效率;在网络的解码层加入ECA确保模型计算的性能,避免因降维导致的精度下降;最后,融合改进的模型输出图与掩膜图细化分割结果。在公开数据集DRIVE、STARE上进行分割实验,模型准确度(accuracy,AC)分别为97.11%、96.32%,灵敏度(sensitivity,SE)为84.55%、83.92%,曲线下方范围的面积(area under curve,AUC)为0.9873和0.9766,分割效果优于其他模型。实验证明了算法的可行性,为后续研究提供科学依据。展开更多
As a ligand-dependent transcription factor,retinoid-associated orphan receptor gt(RORγt)that controls T helper(Th)17 cell differentiation and interleukin(IL)-17 expression plays a critical role in the progression of ...As a ligand-dependent transcription factor,retinoid-associated orphan receptor gt(RORγt)that controls T helper(Th)17 cell differentiation and interleukin(IL)-17 expression plays a critical role in the progression of several inflammatory and autoimmune conditions.An emerging novel approach to the therapy of these diseases thus involves controlling the transcriptional capacity of RORγt to decrease Th17 cell development and IL-17 production.Several RORγt inhibitors including both antagonists and inverse agonists have been discovered to regulate the transcriptional activity of RORγt by binding to orthosteric-or allosteric-binding sites in the ligand-binding domain.Some of small-molecule inhibitors have entered clinical evaluations.Therefore,in current review,the role of RORγt in Th17 regulation and Th17-related inflammatory and autoimmune diseases was highlighted.Notably,the recently developed RORγt inhibitors were summarized,with an emphasis on their optimization from lead compounds,efficacy,toxicity,mechanisms of action,and clinical trials.The limitations of current development in this area were also discussed to facilitate future research.展开更多
文摘临床医生可通过观察眼底视网膜血管及其分支对人体是否患有疾病进行早期诊断,但由于视网膜中的血管错综复杂,模型在分割时会出现对微细血管分割精确度不足的问题。为此,提出一种结合残差模块Res2-net以及高效通道注意力机制(efficient channel attention,ECA)的D-Linknet模型。首先,利用Res2-net代替基础模型中的残差模块Res-net以提升每个网络层的感受野;其次,在Res2-net中添加一种结合压缩激励(squeeze and excitation,SE)和门通道(gated channel transformation,GCT)的注意力机制模块,改善处于复杂背景下的血管分割效果和效率;在网络的解码层加入ECA确保模型计算的性能,避免因降维导致的精度下降;最后,融合改进的模型输出图与掩膜图细化分割结果。在公开数据集DRIVE、STARE上进行分割实验,模型准确度(accuracy,AC)分别为97.11%、96.32%,灵敏度(sensitivity,SE)为84.55%、83.92%,曲线下方范围的面积(area under curve,AUC)为0.9873和0.9766,分割效果优于其他模型。实验证明了算法的可行性,为后续研究提供科学依据。
基金supported by the grants from the Sichuan Science and Technology Program,China(Grant Nos.:2023NSFSC0614 and 2022YFS0624)Southwest Medical University Science and Technology Program,China(Grant No.:2021ZKZD017)+2 种基金the Luzhou Science and Technology Program,China(Grant Nos.:2022-YJY-127,2022YFS0624-B1,2022YFS0624-C1,and 2022YFS0624-B3)the Open Research Project Program funded by the Science and Technology Development Fund(Grant No.:SKL-QRCM(UM)-2020-2022)the State Key Laboratory of Quality Research in Chinese Medicine(University of Macao,Macao,China)(Grant No.:SKL-QRCMOP21006).
文摘As a ligand-dependent transcription factor,retinoid-associated orphan receptor gt(RORγt)that controls T helper(Th)17 cell differentiation and interleukin(IL)-17 expression plays a critical role in the progression of several inflammatory and autoimmune conditions.An emerging novel approach to the therapy of these diseases thus involves controlling the transcriptional capacity of RORγt to decrease Th17 cell development and IL-17 production.Several RORγt inhibitors including both antagonists and inverse agonists have been discovered to regulate the transcriptional activity of RORγt by binding to orthosteric-or allosteric-binding sites in the ligand-binding domain.Some of small-molecule inhibitors have entered clinical evaluations.Therefore,in current review,the role of RORγt in Th17 regulation and Th17-related inflammatory and autoimmune diseases was highlighted.Notably,the recently developed RORγt inhibitors were summarized,with an emphasis on their optimization from lead compounds,efficacy,toxicity,mechanisms of action,and clinical trials.The limitations of current development in this area were also discussed to facilitate future research.
